AGEM Bio Pte. Ltd.

🌟 Exciting News! AGeM Bio at AusBiotech 2024 🌟 We are thrilled to announce that our Co-Founders Dr. Sarah ho and Dr. Jun Yung Woo will be attending the AusBiotech 2024 conference in Melbourne, from October 30 to November 1, 2024! As we continue our journey to advance cutting-edge therapies, including our novel platform for non-viral gene modification of mesenchymal stem cells to target cancers, we're eager to connect with industry leaders, innovators, and collaborators in the biotech community. Join us to discuss the future of cellular therapy and cancer treatment! We look forward to insightful conversations and exploring partnership opportunities. See you at AusBiotech 2024! 👋 #AusBiotech2024 #AGeMBio #Biotechnology #CancerTherapies #GeneTherapy #StemCells #MelbourneEvents #ClinicalTrials #InnovationInBiotech

Exciting news! 📢 We are thrilled to announce the signing of a 4-way Memorandum of Understanding (MOU) between #AGEM Bio Pte. Ltd, Thailand Institute of Scientific and Technological Research (TISTR), Kluaynamthai Hospital, Thailand, and Vega Wellness, Thailand. This landmark agreement signifies our collective commitment to develop cellular therapies in oncology. We were honored to have Ms. Supamas Isarabhakdi, Minister of Higher Education, Science, Research and Innovation (MHESI) of Thailand, in attendance, whose presence underscores the importance of this partnership. Together, we aim to develop the use of engineered stem cells for the treatment of solid tumors, a groundbreaking approach that holds immense potential for improving cancer therapy. We look forward to the positive impact this will have on our communities and industries. A special thank you to everyone who made this possible, including our Founding team: A/Prof Too Heng-Phon, Dr. Sarah ho, Dr. Jun Yung Woo. Here’s to a bright and collaborative future! 🌟 #Partnership #Collaboration #Innovation #MOU #Thailand #Singapore #Biotechnology #MSCtherapy #solidtumortreatment

We are proud to announce that our work using precision-engineered mesenchymal stem cells (#MSC) for treatment in in-vitro and in-vivo models of peritoneal carcinomatosis has recently been published in the Journal of Translational Medicine! Peritoneal carcinomatosis is a terminal disease and patients often suffer from poor prognoses. Using our modified MSCs, we present evidence of the high efficiency against the disease. We show that the co-expression of Interferon-beta within the therapeutic payload dramatically increases efficacy and enhances the treatment outcome. In this work, we also delve into the mechanisms of cellular death by apoptosis and the disruption of mitochondrial potential. #MSC #Celltherapy #cancer #Peritonealcarcinomatosis #AGEMbio Access the article here: https://lnkd.in/gR8q2gbc

Helping patients and meeting clinical unmet needs is at the forefront of what we strive to achieve at AGEM. Thank you The Straits Times for featuring us and highlighting our work. With the help of our collaborators and clinical partners at #NUHS we hope that what we do can bring #impact and help save lives. #gliobastoma #MSC #clinicaltrial #impact #AGEMbio https://lnkd.in/gRAkJtg5

Researchers at NUS Medicine, who successfully used stem cell precision engineering technology targeting late-stage cancer in pets, are seeking validation for the manufacturing processes to prepare the treatment for use in human patients. Led by A/Prof Too Heng-Phon, alongside Dr Sarah ho and Dr Jun Yung Woo, from the Department of Biochemistry and the NUS Centre for Cancer Research, the team has launched AGEM Bio Pte. Ltd. with collaborators, and are aiming to start #human #trials at National University Hospital at the end of 2025, starting with patients battling recurrent #glioblastoma. Read More: https://lnkd.in/g2xQPCk2 #BioTech #MedicalInnovation #StemCellResearch #StemCell #CancerTreatment #NUSMedicine #InspiringInnovators

🚀 Introducing AGEM Bio: Pioneering the Future of Cell Therapy 🚀 We are thrilled to announce the incorporation of AGEM Bio in Q1 of 2024, marking a significant milestone in our journey to revolutionize healthcare. As a proud spin-off from the National University of Singapore (NUS) and the National University Health System (NUHS), AGEM Bio is positioned at the forefront of medical innovation. Our mission is clear and ambitious: to build and advance cell therapy assets that address unmet clinical needs. As an early-stage clinical portfolio company, we are dedicated to transforming groundbreaking research into tangible therapies that can significantly improve patient outcomes. The foundation of AGEM Bio is rooted in deep science and a relentless pursuit of excellence. Our team, comprised of domain experts and passionate innovators, is committed to harnessing the power of cell therapy to tackle some of the most challenging medical conditions. We are excited to embark on this journey and look forward to collaborating with partners, investors, and the broader medical community to bring our vision to life. Together, we can drive the next wave of medical breakthroughs and make a lasting impact on global health. Stay tuned for more updates on our progress and initiatives. The future of cell therapy starts here. 🌟 AGEM Bio – Building the Future of Health 🌟 #HealthcareInnovation #CellTherapy #Biotechnology #ClinicalResearch #MedicalAdvancement #AGEMBio #NUS #NUHS